Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL9195420 | 0.98 | RAB9A (0.47) | RAB9AKDM4EGAANPC1ALDH1A1 | |
| SCHEMBL4138997 | 0.83 | KDM4E (0.58) | RAB9AKDM4EGAAALDH1A1LMNA | |
| SCHEMBL18725065 | 0.80 | CASP3 (0.44) | RAB9AKDM4EGAANPC1AOC3 | |
| SCHEMBL2095368 | 0.80 | APP (0.51) | LMNAAOC3 | |
| SCHEMBL1450948 | 0.80 | RAB9A (0.60) | RAB9AKDM4EGAANPC1ALDH1A1 | |
| SCHEMBL12641895 | 0.80 | APP (0.51) | RAB9AKDM4EGAANPC1ALDH1A1 | |
| SCHEMBL427731 | 0.79 | SMN1; SMN2 (0.59) | RAB9AKDM4EGAANPC1ALDH1A1 | |
| SCHEMBL27635289 | 0.79 | ESR1 (0.37) | GLAMAPTAOC3 | |
| SCHEMBL15130547 | 0.78 | RAB9A (0.44) | RAB9AKDM4EGAANPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3265116 | 0.78 | SMN1; SMN2 (0.58) | RAB9AKDM4EGAANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198220-A1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-07-01 | — | — | US | disclosed |
| US-11001563-B2 | SSAO inhibitor | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-05-11 | — | — | US | disclosed |
| US-20200115352-A1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-04-16 | — | — | US | disclosed |
| EP-3626699-A1 | SSAO INHIBITOR | Shandong Danhong Pharmaceutical Co., Ltd. (CN) | 2020-03-25 | — | — | EP | disclosed |
| CN-1037268-C | Antipicornaviral pyridazinamines | JANSSEM PHARMACEUTICA N V (BE) | 1998-02-04 | — | — | CN | disclosed |
| EP-0207453-B1 | Heterocyclic substituted-phenoxyalkyl-isoxazoles and-furans, their preparation and use as antiviral agents | STERLING WINTHROP INC (US) | 1994-06-22 | — | — | EP | disclosed |
| US-5051437-A | Treatment of rhinovirus or picornaviruses | STERLING DRUG INC. (US) | 1991-09-24 | — | — | US | disclosed |
| US-4857539-A | Heterocyclic substituted-phenoxyalkylisoxazoles as antiviral useful agents | STERLING DRUG INC. (US) | 1989-08-15 | — | — | US | disclosed |
| EP-0207453-A2 | Heterocyclic substituted-phenoxyalkyl-isoxazoles and-furans, their preparation and use as antiviral agents | STERLING WINTHROP INC. (US) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001563-B2 | SSAO inhibitor | SSB, ASAH2, AOX1 | RAB9A 3567/4885KDM4E 2172/4885GAA 51/4885 |
| US-20210198220-A1 | SSAO INHIBITOR | SSB, ASAH2, AOX1 | RAB9A 3567/4885KDM4E 2172/4885GAA 51/4885 |
| US-20200115352-A1 | SSAO INHIBITOR | SSB, ASAH2, AOX1 | RAB9A 3567/4885KDM4E 2172/4885GAA 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.